In vitro and in vivo studies reveal that the hBisAb exhibits a remarkable selectivity for tumor cells over red blood cells, addressing a common challenge of CD47-targeted therapies by minimizing unwanted hematologic effects. The gene discussed is CD47; the disease is neoplasm.